{Reference Type}: Letter
{Title}: [Drug approval: ATEZOLIZUMAB as monotherapy in NSCLC PD-L1 ≥ 50%, without EGFR mutation or ALK rearrangement, for adjuvant treatment after complete surgery and platinum-based chemotherapy].
{Author}: Boudier B;Aldea M;
{Journal}: Bull Cancer
{Volume}: 0
{Issue}: 0
{Year}: Feb 2023 15
{Factor}: 1.318
{DOI}: 10.1016/j.bulcan.2023.01.007
{Abstract}: